• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加权Kaplan-Meier统计量:一类针对删失生存数据的距离检验

Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

作者信息

Pepe M S, Fleming T R

机构信息

Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.

出版信息

Biometrics. 1989 Jun;45(2):497-507.

PMID:2765634
Abstract

A class of statistics based on the integrated weighted difference in Kaplan-Meier estimators is introduced for the two-sample censored data problem. With positive weight functions these statistics are intuitive for and sensitive against the alternative of stochastic ordering. The standard weighted log-rank statistics are not always sensitive against this alternative, particularly if the hazard functions cross. Qualitative comparisons are made between the weighted log-rank statistics and these weighted Kaplan-Meier (WKM) statistics. A statement of null asymptotic distribution theory is given and the choice of weight function is discussed in some detail. Results from small-sample simulation studies indicate that these statistics compare favorably with the log-rank procedure even under the proportional hazards alternative, and may perform better than it under the crossing hazards alternative.

摘要

针对两样本删失数据问题,引入了一类基于Kaplan-Meier估计量的综合加权差异的统计量。对于正权重函数,这些统计量对于随机序的备择假设直观且敏感。标准加权对数秩统计量并非总是对该备择假设敏感,特别是在风险函数交叉时。对加权对数秩统计量和这些加权Kaplan-Meier(WKM)统计量进行了定性比较。给出了零渐近分布理论的陈述,并详细讨论了权重函数的选择。小样本模拟研究的结果表明,即使在比例风险备择假设下,这些统计量也比对数秩检验表现更好,并且在风险函数交叉的备择假设下可能比其表现更佳。

相似文献

1
Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.加权Kaplan-Meier统计量:一类针对删失生存数据的距离检验
Biometrics. 1989 Jun;45(2):497-507.
2
A two-sample test for stochastic ordering with interval-censored data.用于区间删失数据的随机序的两样本检验。
Biometrics. 1994 Mar;50(1):77-87.
3
The simultaneous use of weighted logrank and weighted Kaplan-Meier statistics with clustered right-censored data.同时使用加权对数秩和加权 Kaplan-Meier 统计量对聚类右删失数据进行分析。
Stat Med. 2010 Jan 15;29(1):130-41. doi: 10.1002/sim.3746.
4
A two-sample censored-data rank test for acceleration.一种用于加速度的双样本删失数据秩检验。
Biometrics. 1984 Dec;40(4):1049-62.
5
Some scale estimators and lack-of-fit tests for the censored two-sample accelerated life model.删失双样本加速寿命模型的一些尺度估计量和拟合优度检验
Biometrics. 1998 Sep;54(3):1040-52.
6
Multiple testing procedures based on weighted Kaplan-Meier statistics for right-censored survival data.基于加权Kaplan-Meier统计量的多重检验程序用于右删失生存数据。
Stat Med. 2005 Jan 15;24(1):23-35. doi: 10.1002/sim.1733.
7
A two-sample test sensitive to crossing hazards in uncensored and singly censored data.一种对未删失和单删失数据中的交叉风险敏感的双样本检验。
Biometrics. 1985 Sep;41(3):643-52.
8
Some permutation tests for survival data.一些针对生存数据的排列检验。
Biometrics. 1996 Mar;52(1):87-97.
9
Simultaneous group sequential analysis of rank-based and weighted Kaplan-Meier tests for paired censored survival data.配对删失生存数据的基于秩次和加权Kaplan-Meier检验的同步组序贯分析。
Biometrics. 2005 Sep;61(3):715-20. doi: 10.1111/j.1541-0420.2005.00337.x.
10
Survival estimation using splines.使用样条函数进行生存估计。
Biometrics. 1986 Sep;42(3):495-506.

引用本文的文献

1
Beta blockers linked to reduced 1-Year mortality in critically ill congestive heart failure patients with differential benefits across subgroups.β受体阻滞剂与危重症充血性心力衰竭患者1年死亡率降低相关,且在不同亚组中有不同益处。
Sci Rep. 2025 Sep 2;15(1):32263. doi: 10.1038/s41598-025-17483-3.
2
Independent prognostic importance of endothelial activation and stress index (EASIX) in critically ill patients with heart failure: modulating role of inflammation.内皮激活与应激指数(EASIX)在重症心力衰竭患者中的独立预后重要性:炎症的调节作用
Front Med (Lausanne). 2025 May 1;12:1560947. doi: 10.3389/fmed.2025.1560947. eCollection 2025.
3
Estimating disease onset distribution functions in mutation carriers with censored mixture data.
利用删失混合数据估计突变携带者的疾病发病分布函数。
J R Stat Soc Ser C Appl Stat. 2014 Jan;63(1):1-23. doi: 10.1111/rssc.12025. Epub 2013 Aug 8.
4
Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison.初治溃疡性结肠炎患者中托法替布与维多珠单抗的比较:一项真实世界倾向加权比较
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjae188.
5
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.使用补充性统计方法实现肿瘤学临床试验不良事件评估与报告的现代化:MOTIVATE试验案例研究
Invest New Drugs. 2024 Dec;42(6):664-674. doi: 10.1007/s10637-024-01481-9. Epub 2024 Nov 4.
6
Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies - the example of the Netherlands.超越风险比:免疫肿瘤疗法临床效果量化的适当统计方法 - 以荷兰为例。
BMC Med Res Methodol. 2024 Oct 30;24(1):260. doi: 10.1186/s12874-024-02373-5.
7
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.寡转移非小细胞肺癌:局部及当代全身治疗方法对临床结局的影响
Int J Cancer. 2025 Feb 15;156(4):776-787. doi: 10.1002/ijc.35199. Epub 2024 Sep 25.
8
Estimating survival in data-driven phenotypes of mental health symptoms and peripheral biomarkers: A prospective study.基于数据驱动的心理健康症状表型和外周生物标志物评估生存率:一项前瞻性研究。
Brain Behav Immun Health. 2024 Jun 25;39:100815. doi: 10.1016/j.bbih.2024.100815. eCollection 2024 Aug.
9
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time.使用受限平均生存时间在临床试验中衡量和解释治疗效果
Clin Trials. 2025 Feb;22(1):3-10. doi: 10.1177/17407745241254995. Epub 2024 Jun 13.
10
Different clinical characteristics and outcomes of adult hospitalized SARS-CoV-2 pneumonia patients complicated by cardiovascular events during the first, delta and omicron waves of COVID-19.新型冠状病毒肺炎(COVID-19)第一波、德尔塔变异株和奥密克戎变异株流行期间成年住院的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)肺炎合并心血管事件患者的不同临床特征及结局
Front Epidemiol. 2024 Apr 18;4:1342917. doi: 10.3389/fepid.2024.1342917. eCollection 2024.